Display options
Cite
Song F, Zhang J, Li S, et al. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017;10:4859-4867doi: 10.2147/OTT.S142698.
Song, F., Zhang, J., Li, S., Wu, J., Jin, T., Qin, J., Wang, Y., Wang, M., & Xu, J. (2017). ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. OncoTargets and therapy, 104859-4867. https://doi.org/10.2147/OTT.S142698
Song, Fangbin, et al. "ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy." OncoTargets and therapy vol. 10 (2017): 4859-4867. doi: https://doi.org/10.2147/OTT.S142698
Song F, Zhang J, Li S, Wu J, Jin T, Qin J, Wang Y, Wang M, Xu J. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017 Oct 03;10:4859-4867. doi: 10.2147/OTT.S142698. eCollection 2017. PMID: 29042797; PMCID: PMC5633314.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Oct 03;10:4859-4867. doi: 10.2147/OTT.S142698. eCollection 2017.

ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.

OncoTargets and therapy

Fangbin Song, Jianbing Zhang, Shanbao Li, Junyi Wu, Tao Jin, Jun Qin, Ye Wang, Min Wang, Junming Xu

Affiliations

  1. Department of General Surgery.
  2. Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

PMID: 29042797 PMCID: PMC5633314 DOI: 10.2147/OTT.S142698

Abstract

PURPOSE: Currently, although several clinical trials available give strong suggestions that extension of endocrine therapy has benefits, the risk level at which patients may benefit from extended endocrine therapy remains uncertain. This study aimed to identify the proportion of patients at a substantial risk of late recurrence after 5-year adjuvant endocrine therapy.

PATIENTS AND METHODS: We reviewed 1,056 female patients with primary breast cancer who underwent curative resection between January 2006 and December 2011. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model to identify prognostic factors.

RESULTS: A total of 327 eligible patients were eventually enrolled in this study. Among them, 42 (12.8%) patients suffered from distant metastasis and 34 (10.4%) patients experienced locoregional recurrence after 5-year adjuvant endocrine therapy. In multivariate analysis, patients with more than three positive nodes (hazard ratio [HR] =2.176, 95% CI=1.071-4.421;

CONCLUSION: Late relapse after completion of 5-year adjuvant endocrine therapy was still common, and grade 3 and more than three positive nodes were the risk factors of late recurrence, while grade 3 was the only risk factor of late distant metastasis. These patients might benefit from extended endocrine therapy.

Keywords: Ki-67; aromatase inhibitors; breast neoplasms; extended endocrine therapy; prognosis; tamoxifen

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Clin Cancer Res. 2013 Aug 1;19(15):4196-205 - PubMed
  2. Ann Oncol. 2007 Jan;18(1):45-51 - PubMed
  3. Ann Oncol. 2007 May;18(5):859-67 - PubMed
  4. Ann Oncol. 2015 Aug;26(8):1533-46 - PubMed
  5. Breast Cancer Res Treat. 2009 Mar;114(2):287-99 - PubMed
  6. Lancet. 2002 Jun 22;359(9324):2131-9 - PubMed
  7. Lancet. 2011 Aug 27;378(9793):771-84 - PubMed
  8. PLoS Med. 2010 May 25;7(5):e1000279 - PubMed
  9. Br J Cancer. 2007 May 21;96(10):1504-13 - PubMed
  10. J Clin Oncol. 2008 Mar 1;26(7):1059-65 - PubMed
  11. N Engl J Med. 2016 Jul 21;375(3):209-19 - PubMed
  12. Histopathology. 1991 Nov;19(5):403-10 - PubMed
  13. Breast. 2017 Feb;31:173-180 - PubMed
  14. Lancet. 2005 Jan 1-7;365(9453):60-2 - PubMed
  15. J Clin Oncol. 2016 Apr 1;34(10 ):1134-50 - PubMed
  16. J Clin Oncol. 2003 Oct 1;21(19):3588-93 - PubMed
  17. Lancet Oncol. 2013 Oct;14(11):1067-76 - PubMed
  18. Lancet. 2013 Mar 9;381(9869):805-16 - PubMed
  19. Breast J. 2017 Nov;23 (6):694-705 - PubMed
  20. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  21. Lancet. 1989 Jan 21;1(8630):117-20 - PubMed
  22. J Natl Cancer Inst. 2009 May 20;101(10):736-50 - PubMed
  23. J Clin Oncol. 2014 Jul 20;32(21):2255-69 - PubMed
  24. J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11 - PubMed
  25. J Natl Cancer Inst. 2001 May 2;93(9):684-90 - PubMed

Publication Types